文献速递艾滋病与性传播感染

HIV感染者换用或加用整合酶抑制剂后短期与长期体重变化存在性别差异

Short and Long-term Body Weight Change Following the Switch to or the Addition of Integrase Inhibitors in Persons With HIV Differs by Sex.
PubMed 文献 · Clin Infect Dis · 2025-01-01

研究比较MACS/WIHS联合队列中2007-2020年换用或加用整合酶链转移抑制剂(INSTI)的HIV感染者与继续非INSTI方案者及无HIV者的体重变化。女性换用INSTI后5年体重增加大于男性,绝对增重+3.0 kg vs +1.8 kg,百分比增重+4.6% vs +2.3%,交互作用P<.01。

要点

  • 女性换用INSTI后5年绝对体重增加+3.0 kg(95%CI 2.1-3.9),男性+1.8 kg(95%CI 0.7-2.9)。
  • 女性换用INSTI后5年体重增加百分比+4.6%(95%CI 3.5%-5.7%),男性+2.3%(95%CI 1.0%-3.6%)。
  • 女性换用INSTI后5年臀围增加+2.6 cm,男性+1.2 cm;大腿围女性+1.5 cm,男性-0.2 cm。

核心结论

  • HIV感染者换用INSTI后5年体重变化女性约为男性的2倍,该体重增加差异的心血管代谢影响尚不清楚。

研究设计与样本

  • 研究为MAC S/WIHS联合队列研究(2007-2020年),纳入3464名参与者,比较换用/加用INSTI的HIV感染者与继续非INSTI方案者及无HIV者,按性别分析。

主要发现

  • 女性(411例INSTI、709例非INSTI、818例无HIV)较男性(223例INSTI、412例非INSTI、891例无HIV)更年轻(47.2 vs 54.5岁),非西班牙裔黑人比例更高(65% vs 23%),平均体重指数更高(31.5 vs 26.9 kg/m2)。
  • 女性换用INSTI后5年绝对体重增加+3.0 kg(95%CI 2.1-3.9),男性+1.8 kg(95%CI 0.7-2.9);百分比增重女性+4.6%(95%CI 3.5%-5.7%),男性+2.3%(95%CI 1.0%-3.6%),性别×时间×组交互作用P<.01。
  • 女性换用INSTI后5年臀围增加+2.6 cm(95%CI 1.6-3.6),男性+1.2 cm(95%CI 0.3-2.1);大腿围女性+1.5 cm(95%CI 0.7-2.2),男性-0.2 cm(95%CI -0.9至0.5)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sex-specific, long-term, body weight change in persons with human immunodeficiency virus (PWH) following switch to regimens containing integrase strand transfer inhibitors (INSTIs) is unknown. METHODS: We compared PWH enrolled in the MACS/WIHS Combined Cohort Study (2007-2020) who switched/added an INSTI to their antiretroviral therapy (ART) regimen to those remaining on non-INSTI ART and to people without human immunodeficiency virus (PWOH), by sex. Follow-up time was time since switch visit (or comparable visit in controls). Linear regression mixed-effects models assessed the effects of sex, group, and time upon weight and anthropometric measurements. RESULTS: Of 3464 participants included, women (411 INSTI, 709 non-INSTI, 818 PWOH) compared to men (223 INSTI, 412 non-INSTI, 891 PWOH) were younger (47.2 vs 54.5 years), were majority non-Hispanic Black (65% vs 23%), and had higher mean body mass index (31.5 vs 26.9 kg/m2), respectively. Women switching to INSTIs experienced greater absolute and percentage weight gain compared to men at 5 years: +3.0 kg (95% confidence interval [CI], 2.1-3.9) versus +1.8 kg (95% CI, .7-2.9) and +4.6% (95% CI, 3.5%-5.7%) versus +2.3% (95% CI, 1.0%-3.6%), respectively ([sex × time × group interaction, P < .01). Compared to men, women switching to INSTIs experienced greater hip and thigh circumference gain at 5 years: +2.6 cm (95% CI, 1.6-3.6) versus +1.2 cm (95% CI, .3-2.1) and +1.5 cm (95% CI, .7-2.2) versus -0.2 cm (95% CI, -.9 to .5), respectively. CONCLUSIONS: Weight change among PWH over 5 years after switch to INSTI was 2-fold higher in women than men. The cardiometabolic implications of this difference in weight gain remain unknown.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lahiri CD, Mehta CC, Yang Q, et al. Short and Long-term Body Weight Change Following the Switch to or the Addition of Integrase Inhibitors in Persons With HIV Differs by Sex. Clin Infect Dis. 2025. PMID: 39324701. doi:10.1093/cid/ciae474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。